Previous studies of JAK2V617F mutation prevalence in patients with stroke
| Author, y . | Population . | N . | No. of patients with JAK2V617F mutation (%) . | Age (median) . | Exclusion . | Assay detection limit . |
|---|---|---|---|---|---|---|
| Pardanani et al, 200750 | Patients with stroke referred for thrombophilia testing | 136 | 1 (0.7%) | 56 | Overt MPN | ≤1% |
| Xavier et al, 200851 | Patients with stroke referred for thrombophilia testing | 178 | 2 (1%) | 37 | Overt MPN | 3% |
| Smalberg et al, 200852 | Patients with first ever ischemic stroke, below age 75, with nonatherosclerotic cause | 51 | 0 | NR | Overt MPN | NR |
| Abel et al, 200853 | Patients with stroke referred for thrombophilia testing, without factor V leiden and protrombin gene mutation | 10 | 0 | NR | Overt MPN, malignancy, and HIT | >5% |
| Zerjavic et al, 201054 | Patients with stroke referred for thrombophilia testing | 60 | 2 (3.3%) | 49 | Hematological malignancy, and SVT | NR |
| Chen et al, 201755 | Consecutive patients with ischemic stroke | 153 | 13 (8.5%) | 66.3 (mean) | NR | 0.1% |
| Levraut et al, 202056 | Patients with stroke referred for thrombophilia testing | 30 | 3 (10%) | NR | Laboratory results suggestive of MPN | 0.05% |
| Janjetovic et al, 202157 | Patients with stroke referred for thrombophilia testing | 129 | 8 (6.2%) | NR | Overt MPN | 0.01% |
| Author, y . | Population . | N . | No. of patients with JAK2V617F mutation (%) . | Age (median) . | Exclusion . | Assay detection limit . |
|---|---|---|---|---|---|---|
| Pardanani et al, 200750 | Patients with stroke referred for thrombophilia testing | 136 | 1 (0.7%) | 56 | Overt MPN | ≤1% |
| Xavier et al, 200851 | Patients with stroke referred for thrombophilia testing | 178 | 2 (1%) | 37 | Overt MPN | 3% |
| Smalberg et al, 200852 | Patients with first ever ischemic stroke, below age 75, with nonatherosclerotic cause | 51 | 0 | NR | Overt MPN | NR |
| Abel et al, 200853 | Patients with stroke referred for thrombophilia testing, without factor V leiden and protrombin gene mutation | 10 | 0 | NR | Overt MPN, malignancy, and HIT | >5% |
| Zerjavic et al, 201054 | Patients with stroke referred for thrombophilia testing | 60 | 2 (3.3%) | 49 | Hematological malignancy, and SVT | NR |
| Chen et al, 201755 | Consecutive patients with ischemic stroke | 153 | 13 (8.5%) | 66.3 (mean) | NR | 0.1% |
| Levraut et al, 202056 | Patients with stroke referred for thrombophilia testing | 30 | 3 (10%) | NR | Laboratory results suggestive of MPN | 0.05% |
| Janjetovic et al, 202157 | Patients with stroke referred for thrombophilia testing | 129 | 8 (6.2%) | NR | Overt MPN | 0.01% |
HIT, heparin-induced thrombocytopenia; NR, not reported; SVT, splanchnic venous thrombosis.